Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Reports on Trius Therapeutics

Sort by

Trius: Topline Data of Second Phase III Trial of Tedizolid is Eminent (TSRX, $6.76)

Monday, March 18, 2013 · 8:52 am

Read More

Trius Therapeutics: In an About Face, Congress is Helping Biotech Companies That Are Developing Antibiotics (TSRX, $5.54)

Monday, January 14, 2013 · 8:30 am

Read More

An Update on Trius Therapeutics’ Tedizolid; a Potential Blockbuster for Treating MRSA Infections (TSRX, $5.41)

Wednesday, August 22, 2012 · 11:35 am

Read More

Trius Therapeutics’ Tedizolid has Blockbuster Potential for MRSA Infections (TSRX, $5.05)

Wednesday, May 30, 2012 · 1:45 pm

Read More

There are 4 reports on file.

« Back to Company Reports Index